Clinicopathological study on pIgR expression and tumor progression in advanced colorectal cancer by KIKUCHI Kazuo et al.
Showa Univ J Med Sci 33（2）, 41-46, June 2021
Clinicopathological study on pIgR expression and tumor 
progression in advanced colorectal cancer
Kazuo Kikuchi＊1, 2, 3, Nobuyuki Ohike1, 4, Tomoko Norose1, 4,  
Hitoshi Yoshida3, Takashi Ogawa2 and Toshiko Yamochi1
Received: 25 December 2020 / Accepted: 13 January 2021
Abstract
This study is aimed at investigating the relationship between the polymeric immunoglobulin 
receptor （pIgR） expression and clinicopathological factors in advanced colorectal cancer （CRC） 
patients.  The study involved 47 advanced CRC patients who were surgically resected and 
underwent KRAS gene test.  The pIgR expression was analyzed by immunohistochemistry, and 
the patients were classified into high and low （pIgR-H and pIgR-L, respectively） groups based 
on the staining intensity and range.  A total of 13 cases was classified under the pIgR-H 
group, and the remaining 34 were classified under the pIgR-L group.  Results suggest no 
significant differences in most clinicopathological factors between the pIgR-H and pIgR-L groups, 
although the pIgR-L group had a significantly higher frequency of venous invasion than the 
pIgR-H group, whereas the frequency of KRAS gene mutation was significantly higher in the 
pIgR-H group than that in the pIgR-L group.  The findings in this study showed little significant 
correlation between the pIgR expression and clinicopathological factors in advanced CRC 
patients.  Further research on the biological behavior of pIgR as a drug treatment option for 
KRAS-mutated advanced CRCs is also warranted.
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Introduction
　Secretory IgA （SIgA） antibodies play a crucial 
role as the first line of antigen-specific immune 
defense, which protect the mucosal surfaces against 
environmental pathogens and antigens and maintain 
homeostasis with the commensal microbiota.  The 
polymeric immunoglobulin receptor （pIgR） performs 
two roles : （1）transporting locally produced dimeric 
IgA across mucosal epithelia and （2）serving as the 
precursor of a secretory component, a glycoprotein 
that enhances the immune functions of SIgA.  The 
complex regulation of pIgR expression and transcytosis 
by host and microbial factors is finely tuned to 
optimize the role of SIgA in mucosal immunity. 
Disrupting this regulatory network in disease states 
such as inflammatory bowel disease can adversely 
affect the mucosal homeostasis and systemic sequelae1.  
　pIgR expression plays a role in carcinomas of 
various organs, such as the lung, colon, breast, 
endometrium, ovary, gallbladder, liver, pancreas, 
esophagus, and stomach, and its correlation with 
tumor development and prognosis has been 
considered2-20.  However, while Liu et al.16 reported 
pIgR expression as a poor prognostic factor for liver 
metastasis in colorectal cancer （CRC）, the significance 
of the pIgR expression in CRC remains unknown.  
　This study is aimed at determining the correlation 
between the pIgR expression and clinicopathological 
factors in CRC patients especially those requiring 
adjuvant treatment after surgical resection, with the 
aim of developing a clinical solution to KRAS-
mutant-type CRC.
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　The study pooled 389 advanced CRCs surgically 
resected from January 2016 to December 2018 
at Showa University Fujigaoka Hospital and 
evaluated a final sum of 47 patients who had 
been histopathologically diagnosed with ordinary 
CRC （tubular adenocarcinoma） and undergone a 
KRAS mutation test due to the need for adjuvant 
treatment after surgical resection.  The extracted 
specimens included cases with no obvious lymph node 
metastasis （N0）.  Cases with no pathological lymph 
node metastases, due to distant metastases or other 
factors, were still considered to be at high risk, and 
postoperative chemotherapy was done.
　The immunohistological analysis of the pIgR 
expression in CRC tissues was performed using the 
avidin–biotin complex detection method with standard 
protocols employing a Leica Bond system21.  Briefly, 
formalin-fixed, paraffin-embedded tissue sections were 
pretreated using heat-mediated antigen retrieval with 
sodium citrate buffer for 20 min.  Sections were 
then incubated with primary antibodies against pIgR 
（1 : 500 dilution; no. ab96196 ; Abcam, Cambridge, 
UK） for 15 min.  at room temperature and were 
detected using a horse radish peroxidase-conjugated 
compact polymer system and DAB as the chromogen. 
Sections were then counterstained with hematoxylin.
　Two authors of this study （K.K. and N.O.） who 
were blinded to the clinical parameters separately 
reviewed and scored the immunostained tissue 
sections.  The degree of immunostaining was based 
on the intensity of staining and percentage of cells 
stained.  Staining intensity was graded accordingly 
as follows: 0, negative; 1, weak; 2, moderate; and 3, 
strong.  Moreover, staining percentages were graded 
according to the proportion of positively stained 
tumor cells as follows: 1 for ＜ 30％ positive tumor 
cells ; 2 for 30％–70％ positive tumor cells ; and 3 for
＞ 70％ positive tumor cells.  The pIgR expression 
was evaluated based on the staining index （score : 
1 to 6）.  As an arbitrary but optimal cut-off value, 
we defined a total staining index score of ≤ 4 to 
indicate a low pIgR expression （pIgR-L）, while an 
index score of ≥ 5 to indicate a high pIgR expression 
（pIgR-H） （Figure 1）.  
　A clinical testing company （Bio Medical 
Laboratory, Inc., Kawagoe, Japan） analyzed KRAS 
gene mutations using the PCR-rSSO method.  
　Clinicopathological comparisons between the 
pIgR-H and pIgR-L groups and the KRAS-mutant 
and KRAS-wild-type groups were performed using 
several factors described in the Japanese Classification 
of Colorectal, Appendiceal, and anal carcinoma22.  
　Statistical analyses were carried out using Student’s 
t-test and Welch’s t-test （JMP software program, version 
14; SAS Institute Inc., Cary, NC, USA）.  P＜ 0.05 was 
considered statistically significant.
Results
Immunostaining, scoring, and grouping of pIgR
　The background normal mucosa showed the 
homogeneous diffuse expression of pIgR in the cell 
membrane and cytoplasm of the glands, whereas 
Fig. 1.   Hematoxylin & eosin staining （upper） and immunohistochemical staining of PIGR （lower） 
of colorectal cancers.  The left panel had a score of 2 and the middle panel a score 
of 4, both of which were classified into the pIgR-low group, while the panel on the right 
had a score of 6 and was classified into the pIgR-high group.
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tumor cells showed various staining patterns within 
and between tumors.  Table 1 details the scores of the 
47 cases in this study: 13 cases in the pIgR-H group 
and the remaining 34 cases in the pIgR-L group.  
Clinicopathological comparison between the pIgR-H 
and pIgR-L groups
　Among the factors between the pIgR-H and 
pIgR-L groups, most factors（except for venous 
invasion and KRAS mutation）, such as the sex, 
mean age, location, macroscopic type, mean tumor 
size, circumference ratio, histological type, infiltration 
pattern, depth of invasion, lymphatic invasion, 
perineural invasion, lymph node metastasis, and mean 
survival period, showed no significant differences 
（Table 2）.  A significantly higher frequency of venous 
invasion was found in the pIgR-L group compared to 
that in the pIgR-H group, whereas the frequency of 
KRAS gene mutation was significantly higher in the 
pIgR-H group （77％, 10/13） than that in the pIgR-L 
group （44％, 15/34）.  
Clinicopathological comparison between the KRAS-
mutant and KRAS-wild-type groups
　KRAS mutations were detected in 25 of 47 cases. 
The types of mutations were as follows: A146T, 1case; 
G12A, 2; G12C, 1; G12D, 12; G12V, 2; G13D, and 5; 
Q61H, 1.
　Furthermore, between the KRAS-mutant and 
KRAS-wild-type groups, most factors （except for 
the mean age and pIgR expression）, such as the 
sex, location, macroscopic type, mean tumor size, 
circumference ratio, histological type, infiltration 
pattern, depth of invasion, lymphatic invasion, venous 
invasion, perineural invasion, lymph node metastasis, 
and mean survival period, showed no significant 
differences（Table 3）.  The KRAS-mutant group 
consisted of significantly older subjects, and a high 
pIgR expression was observed to be significantly 
more frequent in the KRAS-mutant group （40％, 
10/25） than that in the KRAS-wild-type group （13％, 
3 /22）.
Table 1.   Patient characteristics
N＝ 47
Age year, mean 67.3
Sex male：female 30（63.8％）：17（36.2％）
Tumor location right：left 14（29.8％）：33（70.2％）
Macroscopic type 1：2：3：4：5 3（6.4％）：25（53.2％）：16（34％）：1（2.1％）：2（4.3％）
Tumor diameter mm, mean 64.4
Circumference ratio ％, mean 85
Histological type adenocarcinoma （well differentiated：moderately differentiated） 15（31.9％）：32（68.1％）
Infiltration pattern expansive：intermediate：infiltrative 18（38.3％）：7（14.9）：22（46.8％）
Depth of tumor invasion T2：T3：T4 2（4.3％）：30（63.8％）：15（31.9％）
Lymphatic invasion none：minimal：moderate：severe 5（10.6％）：33（70.2％）：6（12.8％）：3（6.4％）
Venous invasion none：minimal：moderate：severe 0（0％）：12（25.5％）：28（59.6％）：7（14.9％）
Perineural invasion none：intramural only：extramural 16（34.0％）：17（36.2％）：14（29.8％）
Lymph node metastasis N0：N1：N2：N3 15（31.9％）：14（29.8％）：10（21.3％）：8（17.0％）
Survival period month, mean 28.6
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Table 2.   Clinicopathological comparisons between the pIgR-H and pIgR-L groups
Group
pIgR-H group pIgR-L group
p-value
（13 case） （34 case）
Sex （male：female） 7：6 23：11 NS
Age （mean, years） 66 68 NS
Tumor location （right：left） 4：9 10：24 NS
Macroscopic type （1：2：3：4：5） 1：8：3：0：1 2：17：13：1：1 NS
Tumor diameter （mean, mm） 67.2 63.3 NS
Circumference ratio （mean, ％） 89 83 NS
Histological type, Adenocarcinoma 
（well differentiated：moderately differentiated） 6：7 9：25 NS
Infiltration pattern （expansive：intermediate：infiltrative） 5：2：6 13：5：16 NS
Depth of tumor invasion （T2：T3：T4） 2：4：7 0：26：8 NS
Lymphatic invasion （none：minimal：moderate：severe） 1：10：2：0 4：23：4：3 NS
Venous invasion（none：minimal：moderate：severe） 0：6：7：0 0：6：21：7 p＝ 0.02
Perineural invasion （none：intramural only：extramural） 5：5：3 11：12：11 NS
Lymph node metastasis （N0：N1：N2：N3） 5：5：0：3 10：9：10：5 NS
Survival period （month, mean） 23（n＝ 12） 18（n＝ 27） NS
RAS gene （mutant：wild） 10：3 15：19 p＝ 0.04
NS: not significant
Table 3.   Clinicopathological comparisons between the KRAS-mutant and KRAS-wild-type groups
Group
KRAS-Mutant type KRAS-Wild type
p-value
（n＝ 25） （n＝ 22）
Sex （male：female） 16：9 14：8 NS
Age （mean, years） 70 64 0.04
Tumor location （right：left） 10：15 4：18 NS
Macroscopic type （1：2：3：4：5） 3：13：8：0：1 0：12：8：1：1 NS
Tumor diameter （mean, mm） 63 66 NS
Circumference ratio （mean, ％） 86％ 83％ NS
Histological type, Adenocarcinoma
（well differentiated：moderately differentiated） 11：14 4：18 NS
Infiltration pattern （expansive：intermediate：infiltrative） 0：22：3 0：18：4 NS
Depth of tumor invasion （T2：T3：T4） 2：15：8 0：15：7 NS
Lymphatic invasion（none：minimal：moderate：severe） 3：20：2：0 2：13：4：3 NS
Venous invasion（none：minimal：moderate：severe） 0：7：16：2 0：5：12：5 NS
Perineural invasion（none：intramural only：extramural） 8：8：9 8：9：5 NS
Lymph node metastasis （N0：N1：N2：N3） 10：6：6：3 5：8：4：5 NS
Survival period 28（n＝ 24） 29（n＝ 18） NS
pIgR expression （high：low） 10：15 3：19 0.04
NS: not significant




　The mucosal surface of the gastrointestinal tract is 
overwhelmed with various stimuli.  Protection from 
these stimuli is important, and innate and adaptive 
immunities must function cooperatively.  The surfaces 
of mucosal sites are covered by epithelial cells, such 
as the intestinal epithelial cells （IECs）.  IECs form 
a physical barrier and drive innate and adaptive 
immunity against invading pathogens to maintain 
intestinal homeostasis.  The most important adaptive 
immune system in mucosal sites is the mucosal 
immune system, and the main player in this system 
is the polymeric immunoglobulins（pIgs）, which 
are produced by antibody-secreting plasma̶cells 
that accumulate in the lamina propria.  In order to 
exert a protective function, pIgs are transported to 
the luminal side, across IECs, then finally released 
into the intestinal lumen.  This process is called 
transcytosis and is mediated by a glycoprotein, pIgR9.
　While the abnormal expression of pIgR is generally 
known in malignant tumors, the clinical relevance 
and potential function of pIgR in the tumor cells 
remain to be topics to be explored.  Studies on 
the relationship between the pIgR expression 
and malignant behaviors yield varying findings 
across cancers.  Moreover, concerning studies on 
gastrointestinal and hepatobiliary-pancreatic cancers, 
Ai et al. showed that a high expression of pIgR was 
significantly associated with early recurrence in early-
stage hepatocellular carcinoma （HCC） and hepatitis 
B surface antigen-positive HCC patients8, whereas 
Richard et al. conversely reported that a high pIgR 
expression independently predicted a decreased risk of 
recurrence and an improved survival in patients with 
adenocarcinoma of the upper gastrointestinal tract10. 
In addition, a high tumor-specific pIgR expression 
showed a more favorable tumor phenotype, while 
a low expression independently predicted a shorter 
survival in patients with pancreatic and periampullary 
cancer11.
　As revealed in the study of Liu et al.16, a positive 
expression of pIgR was significantly associated with 
a poor prognosis in colon carcinoma patients with 
hepatic metastasis.  In our study, however, significant 
differences on clinicopathological examinations 
between the pIgR-H and pIgR-L groups were found 
in only a few factors （venous invasion and KRAS 
mutation）.  Due to the small number of cases, there 
is little certainty to deduce that pIgR expression 
cannot be a significant prognostic factor.
　Patients with gene mutations are considered 
“mutant type,” whereas those without are considered 
“wild type.” KRAS mutations have emerged as 
aggressive drivers of disease.  However, while it 
has been more than 30 years since the discovery 
of the role of KRAS in transforming cells and 
driving cancer progression, there are still currently no 
pharmaceutical breakthroughs that are able to address 
the activating mutations of KRAS or to selectively 
down-regulate KRAS mRNA and proteins, nor are 
there any inhibiting downstream effector pathways in 
clinical trials.  This elevates the problem we already 
face in treating the three most deadly cancers̶
pancreatic cancer, non-small-cell lung cancer, and 
CRC̶as KRAS mutations are associated with a poor 
prognosis in these tumor histotypes23.  
　Moreover, a significant correlation was found 
between KRAS mutations and the pIgR expression, 
which no previous research was able to reveal9.  The 
molecular mechanism underlying the correlation is yet 
unknown, and perhaps a coincidence; nevertheless, the 
development of pIgR-targeted therapeutics is expected 
to be useful in treating KRAS-mutant-type CRCs.
Conclusions
　The findings in this study reveal that there is little 
significant correlation between pIgR expression and 
clinicopathological factors in patients with advanced 
CRC.  Further accumulation of cases and careful 
examination are required whether studies focusing on 
pIgR as a treatment strategy for KRAS-mutant-type 
CRC may be meaningful or not.
　This study was performed in accordance with the Helsinki 
Declaration, and the Research Ethics Committee at Showa 
University Fujigaoka Hospital approved the protocol 
（Approval number; No. F2019C51）.
Funding
　None
Conflict of Interest disclosure
　None
References
1. Johansen FE, Kaetzel CS. Regulation of the polymeric 
immunoglobulin receptor and IgA transport: new 
advances in environmental factors that stimulate pIgR 
expression and its role in mucosal immunity. Mucosal 
Immunol. 2011;4:598-602. 
2. Poger ME, Hirsch BR, Lamm ME. Synthesis of secre-
tory component by colonic neoplasms. Am J Pathol. 




3. Harris JP, Caleb MH, South MA. Secretory compo-
nent in human mammary carcinoma. Cancer Res. 
1975;35:1861-1864. 
4. Harris JP, South MA. Secretory component: a glandular 
epithelial cell marker. Am J Pathol. 1981;105:47-53. 
5. DeSouza LV, Krakovska O, Darfler MM, et al. 
mTRAQ-based quantification of potential endometrial 
carcinoma biomarkers from archived formalin-fixed 
paraffin-embedded tissues. Proteomics. 2010;10:3108-
3116.
6. Rossel M, Billerey C, Bittard H, et al. Alterations in 
polymeric immunoglobulin receptor expression and 
secretory component levels in bladder carcinoma. Urol 
Res. 1991;19:361-366.
7. Rossel M, Seilles E, Voigt JJ, et al. Polymeric Ig 
receptor expression in hepatocellular carcinoma. Eur J 
Cancer. 1992;28A:1120-1124.
8. Ai J, Tang Q, Wu Y, et al. The role of polymeric 
immunoglobulin receptor in inflammation-induced tumor 
metastasis of human hepatocellular carcinoma. J Natl 
Cancer Inst. 2011;103:1696-1712. 
9. Berntsson J, Lundgren S, Nodin B, et al. Expres-
sion and prognostic significance of the polymeric 
immunoglobulin receptor in epithelial ovarian cancer. 
J Ovarian Res. 2014;26:26.（accessed 2019 Aug 13） 
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC3938822/pdf/1757-2215-7-26.pdf
10. Fristedt R, Gaber A, Hedner C, et al. Expression and 
prognostic significance of the polymeric immunoglobulin 
receptor in esophageal and gastric adenocarcinoma. 
J Transl Med. 2014;12:83.（accessed 2019 Oct 23） 
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4021601/pdf/1479-5876-12-83.pdf
11. Fristedt R, Elebro J, Gaber A, et al. Reduced expres-
sion of the polymeric immunoglobulin receptor in 
pancreatic and periampullary adenocarcinoma signifies 
tumour progression and poor prognosis. PLoS One. 
2014;14:e112728.（accessed 2019 Nov 2） Avail-
able from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4232506/pdf/pone.0112728.pdf
12. Xiao T, Ying W, Li L, et al. An approach to studying 
lung cancer-related proteins in human blood. Mol Cell 
Proteomics. 2005;4:1480-1486.
13. Rossel M, Brambilla E, Billaud M, et al. Nonspecific 
increased serum levels of secretory component in 
lung tumors: relationship to the gene expression of 
the transmembrane receptor form. Am J Respir Cell 
Mol Biol. 1993;9:341-346.
14. Makawita S, Smith C, Batruch I, et al. Integrated 
proteomic profiling of cell line conditioned media 
and pancreatic juice for the identification of pan-
creatic cancer biomarkers. Mol Cell Proteomics. 
2011;10:M111.008599.（accessed 2019 Jul 23） Avail-
able from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC3205865/pdf/M111.008599.pdf
15. Kvale D, Norstein J, Meling GI, et al. Circulating 
secretory component in relation to early diagnosis and 
treatment of liver metastasis from colorectal carcino-
mas. J Clin Pathol. 1992;45:568-571.
16. Liu F, Ye P, Bi T, et al. COLORECTAL polymeric 
immunoglobulin receptor expression is correlated 
with hepatic metastasis and poor prognosis in colon 
carcinoma patients with hepatic metastasis. Hepatogas-
troenterology. 2014:61:652-659. 
17. Arumugam P, Bhattacharya S, Chin-Aleong J, et al. 
Expression of polymeric immunoglobulin receptor and 
stromal activity in pancreatic ductal adenocarcinoma. 
Pancreatology. 2017;17:295-302.
18. Yue X, Ai J, Xu Y, et al. Polymeric immunoglobulin 
receptor promotes tumor growth in hepatocellular 
carcinoma. Hepatology. 2017;65:1948-1962.
19. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab 
and chemotherapy as initial treatment for metastatic 
colorectal cancer. N Engl J Med. 2009;360:1408-1417. 
20. Bokemeyer C, Van Cutsem E, Rougier P, et al. 
Addition of cetuximab to chemotherapy as first-line 
treatment for KRAS wild-type metastatic colorectal 
cancer: pooled analysis of the CRYSTAL and OPUS 
randomised clinical trials. Eur J Cancer. 2012;48:1466-
1475. 
21. Ohkuma R, Yada E, Ishikawa S, et al. High expres-
sion of olfactomedin-4 is correlated with chemoresis-
tance and poor prognosis in pancreatic cancer. PLoS 
One. 2020;15:e0226707. （accessed 2020 Jan 19） 
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC6953839/pdf/pone.0226707.pdf
22. Japanese Society for Cancer of the Colon and Rec-
tum. Japanese Classification of colorectal, appendiceal, 
and anal carcinoma. 3rd English ed. Tokyo: Kanehara; 
2019.
23. Porru M, Pompili L, Caruso C, et al. Targeting KRAS 
in metastatic colorectal cancer : current strategies 
and emerging opportunities. J Exp Clin Cancer Res. 
2018;37:57.（accessed 2019 Feb 1） Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850913/
pdf/13046_2018_Article_719.pdf
